메뉴 건너뛰기




Volumn 79, Issue 1-2, 2010, Pages 93-97

Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation

Author keywords

Autologous peripheral blood stem cell transplantation; BEAM; Engraftment; Filgrastim; Pegfilgrastim

Indexed keywords

ANTIBIOTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

EID: 78149444289     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320604     Document Type: Article
Times cited : (7)

References (19)
  • 3
    • 0027534424 scopus 로고
    • The place of high-dose beam therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: A single-center 8-year study of 155 patients
    • Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH: The place of high-dose beam therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: a single-center 8-year study of 155 patients. Blood 1993; 81: 1137-1145.
    • (1993) Blood , vol.81 , pp. 1137-1145
    • Chopra, R.1    McMillan, A.K.2    Linch, D.C.3    Yuklea, S.4    Taghipour, G.5    Pearce, R.6    Patterson, K.G.7    Goldstone, A.H.8
  • 4
    • 0027404777 scopus 로고
    • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
    • Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
    • (1993) Lancet , vol.341 , pp. 1051-1054
    • Linch, D.C.1    Winfield, D.2    Goldstone, A.H.3    Moir, D.4    Hancock, B.5    McMillan, A.6    Chopra, R.7    Milligan, D.8    Hudson, G.V.9
  • 8
    • 66549094588 scopus 로고    scopus 로고
    • Hematopoietic growth factors: ESMO recommendations for the applications
    • Crawford J, Caserta C, Roila F: Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol 2009; 20: 162-165.
    • (2009) Ann Oncol , vol.20 , pp. 162-165
    • Crawford, J.1    Caserta, C.2    Roila, F.3
  • 10
    • 55049132537 scopus 로고    scopus 로고
    • Highdose chemotherapy with BEAM or busulphan/ melphalan and thiotepa followed by hematopoietic cell transplantation in malignant lymphoma
    • Zaucha R, Gooley T, Holmberg L, Gopal AK, Press O, Maloney D, Bensinger WI: Highdose chemotherapy with BEAM or busulphan/ melphalan and thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma 2008; 49: 1899-1906.
    • (2008) Leuk Lymphoma , vol.49 , pp. 1899-1906
    • Zaucha, R.1    Gooley, T.2    Holmberg, L.3    Gopal, A.K.4    Press, O.5    Maloney, D.6    Bensinger, W.I.7
  • 11
    • 36549080513 scopus 로고    scopus 로고
    • BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non- Hodgkin's lymphoma patients: Comparative analysis of efficacy and toxicity
    • Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C: BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non- Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 2008; 87: 43-48.
    • (2008) Ann Hematol , vol.87 , pp. 43-48
    • Jo, J.C.1    Kang, B.W.2    Jang, G.3    Sym, S.J.4    Lee, S.S.5    Koo, J.E.6    Kim, J.W.7    Kim, S.8    Huh, J.9    Suh, C.10
  • 12
    • 84858864919 scopus 로고    scopus 로고
    • R development core team: R: A Language and Environment for Statistical Computing
    • R development core team: R: a Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2009. www.R-project.org.
    • (2009) R Foundation for Statistical Computing
  • 14
    • 0036467835 scopus 로고    scopus 로고
    • Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer
    • Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727-731.
    • (2002) J Clin Oncol , vol.20 , pp. 727-731
    • Holmes, F.A.1    O'Shaughnessy, J.A.2    Vukelja, S.3    Jones, S.E.4    Shogan, J.5    Savin, M.6    Glaspy, J.7    Moore, M.8    Meza, L.9    Wiznitzer, I.10    Neumann, T.A.11    Hill, L.R.12    Liang, B.C.13
  • 15
    • 36549090123 scopus 로고    scopus 로고
    • Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas
    • Ballestrero A, Boy D, Gonella R, Miglino M, Clavio M, Barbero V, Nencioni A, Gobbi M, Patrone F: Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Ann Hematol 2008; 87: 49-55.
    • (2008) Ann Hematol , vol.87 , pp. 49-55
    • Ballestrero, A.1    Boy, D.2    Gonella, R.3    Miglino, M.4    Clavio, M.5    Barbero, V.6    Nencioni, A.7    Gobbi, M.8    Patrone, F.9
  • 18
    • 77955888016 scopus 로고    scopus 로고
    • Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma
    • Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F, Boehm KA, Asmar L, Beveridge R: Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10: 186-191.
    • (2010) Clin Lymphoma Myeloma Leuk , vol.10 , pp. 186-191
    • Rifkin, R.1    Spitzer, G.2    Orloff, G.3    Mandanas, R.4    McGaughey, D.5    Zhan, F.6    Boehm, K.A.7    Asmar, L.8    Beveridge, R.9
  • 19
    • 0038663017 scopus 로고    scopus 로고
    • BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy
    • Jantunen E, Kuittinen T, Nousiainen T: BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma 2003; 44: 1151-1158.
    • (2003) Leuk Lymphoma , vol.44 , pp. 1151-1158
    • Jantunen, E.1    Kuittinen, T.2    Nousiainen, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.